Active Filter(s):
Details:
Collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC. By combining SI-B001 with Osimertinib, we believe it has the potential to provide more effective treatment options for patients with NSCLC.
Lead Product(s): SI-B001,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: SI-B001
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 13, 2022